---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-008133"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:41:20.262313+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# KALA BIO Q1 net loss $11.8M; Phase 2b CHASE trial enrolling, topline data by year-end 2024

## Summary
- Phase 2b CHASE trial of KPI-012 for PCED enrolling; topline data expected by year-end 2024.
- Cash and equivalents $48.5M as of March 31, 2024; with CIRM award, funds operations into Q3 2025.
- Q1 2024 net loss $11.8M ($4.20/share) vs $14.5M ($6.99/share) in Q1 2023; operating loss $11.9M.
- R&D expenses rose to $6.4M from $4.0M year-over-year, driven by KPI-012 development.
- Gross proceeds of $8.6M from March 2024 private placement partially offset cash used in ops.

## SEC filing metadata
- accession: 0001558370-24-008133
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837024008133/0001558370-24-008133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837024008133/kala-20240514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-008133
- JSON: https://secwatch.observer/filing/0001558370-24-008133.json
- Plain text: https://secwatch.observer/filing/0001558370-24-008133.txt

## Key facts
- Earnings Releases
  KALA BIO, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 14, 2024, KALA BIO, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a general business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837024008133/0001558370-24-008133-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.